Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase Inhibitors

A new chemical series, triazolo[4,5-b]pyridines, has been identified as an inhibitor of PIM-1 by a chemotype hopping strategy based on a chemically feasible fragment database. In this case, structure-based virtual screening and in silico chemogenomics provide added value to the previously reported strategy of prioritizing among proposed novel scaffolds. Pairwise comparison between compound 3, recently discontinued from Phase I clinical trials, and molecule 8, bearing the selected novel scaffold, shows that the primary activities are similar (IC50 in the 20 to 150 nM range). At the same time, some ADME properties (for example, an increase of more than 45% in metabolic stability in human liver microsomes) and the off-target selectivity (for example, an increase of more than 2 log units in IC50 vs. FLT3) are improved, and the intellectual property (IP) position is enhanced. The discovery of a reliable starting point that fulfills critical criteria for a plausible medicinal chemistry project is demonstrated in this prospective study.

[1]  Jos Domen,et al.  The primary structure of the putative oncogene pim-1 shows extensive homology with protein kinases , 1986, Cell.

[2]  J. A. Grant,et al.  A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..

[3]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[4]  Thierry Langer,et al.  Comparative Performance Assessment of the Conformational Model Generators Omega and Catalyst: A Large-Scale Survey on the Retrieval of Protein-Bound Ligand Conformations , 2006, J. Chem. Inf. Model..

[5]  J. Andrew Grant,et al.  A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..

[6]  Lisa S. Chen,et al.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.

[7]  Andy Jennings,et al.  Selection of Molecules Based on Shape and Electrostatic Similarity: Proof of Concept of "Electroforms" , 2007, J. Chem. Inf. Model..

[8]  Manuel Urbano-Cuadrado,et al.  Centralizing discovery information: from logistics to knowledge at a public organization. , 2011, Combinatorial chemistry & high throughput screening.

[9]  R. Strasser,et al.  Transcriptional regulation of Pim-1 kinase in vascular smooth muscle cells and its role for proliferation , 2010, Basic Research in Cardiology.

[10]  R. Reeves,et al.  Recombinant human pim-1 protein exhibits serine/threonine kinase activity. , 1991, The Journal of biological chemistry.

[11]  A. Hölscher,et al.  Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. , 2009, Anticancer research.

[12]  J. Oyarzábal,et al.  Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. , 2011, Cancer letters.

[13]  Z. Wang,et al.  Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. , 2001, Journal of veterinary science.

[14]  Julen Oyarzabal,et al.  Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists. , 2009, Journal of medicinal chemistry.

[15]  J. Oyarzábal,et al.  Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[16]  Stefan Knapp,et al.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.

[17]  J. Arthur,et al.  Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL , 2006, BMC Cell Biology.

[18]  A. Kraft,et al.  The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway , 1999, Oncogene.

[19]  B. Cheson,et al.  Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study , 2008, Leukemia & lymphoma.

[20]  A. Berns,et al.  Proviral activation of the putative oncogene Pim‐1 in MuLV induced T‐cell lymphomas. , 1985, The EMBO journal.

[21]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[22]  Jos Jonkers,et al.  Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors , 2004, Molecular and Cellular Biology.

[23]  O. Franco,et al.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma , 2010, Oncogene.

[24]  P. Koskinen,et al.  Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site , 2004, FEBS letters.

[25]  Jonas Boström,et al.  Assessing the performance of OMEGA with respect to retrieving bioactive conformations. , 2003, Journal of molecular graphics & modelling.

[26]  Jonas Boström,et al.  Reproducing the conformations of protein-bound ligands: A critical evaluation of several popular conformational searching tools , 2001, J. Comput. Aided Mol. Des..

[27]  R. Zhao,et al.  Tumorigenesis and Neoplastic Progression Hypoxia-Mediated Up-Regulation of Pim-1 Contributes to Solid Tumor Formation , 2010 .

[28]  D. Agus,et al.  Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes , 2009, Molecular Cancer Therapeutics.

[29]  C. Ducrocq,et al.  11H-Pyrido[3',2':4,5]pyrrolo[2,3-g]isoquinoléines (aza-7 ellipticines) substituées sur leur position 6 , 1981 .

[30]  Wim Quint,et al.  Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.

[31]  J. Andrew Grant,et al.  Molecular shape and electrostatics in the encoding of relevant chemical information , 2005, J. Comput. Aided Mol. Des..

[32]  A. Pierce,et al.  Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. , 2008, Journal of medicinal chemistry.

[33]  F. Sigaux,et al.  The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Knapp,et al.  Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.

[35]  S. Knapp,et al.  Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. , 2007, Cancer research.

[36]  Min Liu,et al.  Overexpression of PIM‐1 is a potential biomarker in prostate carcinoma , 2005, Journal of surgical oncology.

[37]  R. Reeves,et al.  PIM1 Phosphorylates and Negatively Regulates ASK1-mediated Apoptosis , 2009, Oncogene.